Outcome and management of hepatitis C in liver transplant recipients

Clinical Infectious Diseases

Volumn 37, Issue 6, 2003, Pages 807-812

  Chan, Susan E ^a   Rosen, Hugo R ^a  

^a PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; CALCINEURIN INHIBITOR; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN;

ALLOGRAFT; ARTICLE; BONE MARROW SUPPRESSION; CYTOPENIA; DEPRESSION; DRUG EFFICACY; DRUG TOLERABILITY; FLU LIKE SYNDROME; GRAFT FAILURE; GRAFT INFECTION; HEMOLYSIS; HEPATITIS C; HEPATITIS C VIRUS; HISTOLOGY; HISTORY; HUMAN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MONOTHERAPY; MORTALITY; NEPHROTOXICITY; PRIORITY JOURNAL; RECIPIENT; RECURRENT DISEASE; REINFECTION; REOPERATION; RISK FACTOR; SIDE EFFECT; TREATMENT INDICATION; TREATMENT OUTCOME; VIREMIA; VIRUS LOAD;

ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; RECURRENCE; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0141676159     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/377605     Document Type: Article

References (37)

1. Fukumoto T, Berg T, Ku Y, et al. Viral Dynamics of hepatitis C early after orthotopic liver transplantation: evidence for rapid turnover of serum virions. Hepatology 1996; 24:1351-4.
2. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122:889-96.
3. Gane EJ, Portmann BC, Naoumouv NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334:821-7.
4. Berenguer M, Ferrell L, Watson J, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32:673-84.
5. Berenguer M, Prieto M, Rayon JM, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after transplantation. Hepatology 2000; 32:852-8.
6. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112:463-72.
7. Berenguer M, Prieto M, San Juan F, et al. Contribution of donor age to the recent decrease in patient survival among hepatitis C virus-infected liver transplant recipients. Hepatology 2002; 36:202-10.
8. Baron PW, Sindram D, Higdon D, et al. Prolonged rewarming time during allograft implantation predisposes to recurrent hepatitis C infection after liver transplantation. Liver Transpl 2000; 6:407-12.
9. Razonable RR, Burak KW, vanCruijsen H, et al. The pathogenesis of hepatitis C virus is influenced by cytomegalovirus. Clin Infect Dis 2002; 35:974-81.
10. Rosen HR, Shackelton CR, Higa L, et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol 1997; 92:1453-7.
11. Gretch DR, Bacchi CE, Corey L, et al. Persistent hepatitis C virus infection after liver transplantation: clinical and virological features. Hepatology 1995; 22:1-9.
12. Gane EJ, Naoumov NV, Qian K-P, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996; 110:167-77.
13. Charlton M, Seaberg E, Wiesner R, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28:823-30.
14. Charlton M. Pre-emptive treatment of recurrent hepatitis C infection. Liver Transpl 2002; 8(Suppl):S50-4.
15. Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002; 8:350-5.
16. Everson GT, Trotter J, Kugelmas M. Long-term outcome of patients with chronic hepatitis C and decompensated liver disease treated with the LADR protocol (Low-accelerating-dose regimen) [abstract]. Hepatology 2002; 36:297A.
17. Mazzaferro V, Tagger A, Schiavo M, et al. Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin therapy. Transplant Proc 2001; 33:1355-7.
18. Peck-Radosavljevic M, Hofmann H, Ferenci P, Rasoul-Rockenschaub S. Sensitivity to IFN-A in patients with recurrent hepatitis C scheduled for combination therapy after orthotopic liver transplantation [abstract]. Hepatology 2002; 36:182A.
19. Saab S, Ly D, Han SB, et al. Is it cost-effective to treat recurrent hepatitis C infection in orthotopic liver transplantation patients? Liver Transpl 2002; 8:449-57.
20. Gane E. Treatment of recurrent hepatitis C. Liver Transpl 2002; 8(Suppl):S28-37.
21. Jain AB, Eghtesad B, Venkataramanan R, et al. Ribavirin dose modification based on renal function is necessary to reduce hemolysis in liver transplant patients with hepatitis C virus infection. Liver Transpl 2002; 8:1007-13.
22. Gopal D, Rabkin JM, Berk B, Corless CL, Orloff SL, Rosen HR. Treatment of progressive HCV recurrence following liver transplantation with combination interferon and ribavirin therapy. Liver Transpl 2001; 7:181-90.
23. de Vera ME, Smallwood GA, Rosado K, et al. Interferon-α and ribavirin for the treatment of recurrent hepatitis C after liver transplantation. Transplantation 2001; 71:678-86.
24. Narayanan Menon KV, Poterucha JJ, El-Amin OM, et al. Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy. Liver Transpl 2002; 8:623-9.
25. Bizollon T, Palazzo U, Ducerf C, et al. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 1997; 26:500-4.
26. Ahmad J, Dodson SF, Demetris AJ, Fung JJ, Shakil AO. Recurrent hepatitis C after liver transplantation: a nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin. Liver Transpl 2001; 7:863-9.
27. Alberti AB, Belli LS, Airoldi A, et al. Combined therapy with interferon and low-dose ribavirin in posttransplantation recurrent hepatitis C: a pragmatic study. Liver Transpl 2001; 7:870-6.
28. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, et al. Combination of interferon alfa-2B and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl 2002; 8:1000-6.
29. Lavezzo B, Franchello AA, Smeldie A, et al. Treatment of recurrent hepatitis C in liver transplants: efficacy of a six versus 12 month course of interferon alfa 2b with ribavirin. J Hepatol 2002; 37:247-52.
30. Khatib MA, Arenas JI, Carey E, et al. Treatment with combination of peg IFN α-2B and ribavirin suppresses viral replication in liver transplantation recipients with recurrent HCV hepatitis [abstract]. Hepatology 2002; 36:182A.
31. Neff G, Montalbano M, Lee YM, Slapak G, Safdar K, Morrero R. Naive treatment results in liver transplant recipients with hepatitis C virus recurrence (HCV-R) using pegylated interferon alpha-2B combined with ribavirin: preliminary results [abstract]. Hepatology 2002; 36:183A.
32. Ferenci P, Peck-Radosalvljevic M, Vogel W, Voigt M, Marks IM, Pappas SC. Pegylated (40kDa) interferon alfa-2A (Pegysus) in post-liver transplant recipients with established recurrent hepatitis C: a preliminary report [abstract]. Am J Transplant 2001; 1(Suppl 1):158.
33. Gopal DV, Rosen HR. Duration of antiviral therapy for cholestatic HCV recurrence may need to be indefinite. Liver Transpl 2003; 9:348-53.
34. Rosen HR. Retransplantation for hepatitis C: implications of different policies. Liver Transpl 2000; 6:41-6.
35. Rosen HR, Martin P. Hepatitis C infection in patients undergoing liver retransplantation. Transplantation 1998; 66:1612-6.
36. Berenguer M, Prieto M, Palau A, et al. Severe recurrent hepatitis C after liver transplantation for hepatitis C virus-related graft cirrhosis. Liver Transpl 2003; 9:228-35.
37. Lin CC, Lau JY. Specific, sensitive and accurate LC-MS/MS method for the measurement of levovirin in rat and monkey plasma. J Pharm Biomed Anal 2002; 30:239-46.